Compare Fubotv Inc (FUBO) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Revvity Inc — how do they compare? Fubotv Inc trades at $8.84 (market cap $1.02B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 16.6× Fubotv Inc's market cap, and Revvity Inc pays a 0.18% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Revvity Inc for 12 Days on average.
| FUBO | RVTY | |
|---|---|---|
Market Cap | $1.02B | $16.98B |
Volume | 978,631 | 1,456,900 |
Sector | Media | Health |
52-Week High | $48.96 | $157.36 |
52-Week Low | $8.09 | $82.26 |
Typical Hold Time | 35 Days | 12 Days |
Enterprise Value | $1.19B | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.35, up 1.08% with bearish technical signals but attractive valuation metrics including P/E of 2.43 and P/S of 0.19. The company shows improving financials with revenue growth to $1.62B in 2024 and projected profitability in 2025. Recent developments include new sports streaming agreements and Disney partnership integration driving subscriber growth.
FUBO presents a turnaround opportunity with deep valuation discounts and projected EBITDA growth, though execution risks remain high. The stock offers significant upside to analyst consensus target of $63.38 but faces challenges from persistent cash burn and competitive streaming landscape. Investors should weigh the potential for operational improvements against ongoing financial volatility.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
